Recent developments include regulatory approvals, asset sales, and financial results impacting Fortress Biotech and its subsidiaries.

• Fortress Biotech held its Q2 2026 earnings call, discussing financial results and operational updates [N1].
• The company’s subsidiary Cyprium Therapeutics closed the sale of a Rare Pediatric Disease Priority Review Voucher for $205 million in March 2026 [N3].
• Fortress Biotech announced FDA approval of ZYCUBO, the first and only approved treatment for Menkes disease in the U.S., in January 2026 [N8].
• Cyprium Therapeutics planned to sell a $250 million Priority Review Voucher, with shares rising on the news in February 2026 [N5].
• Fortress Biotech’s Q2 2026 earnings call highlighted ongoing development and commercialization efforts [N2].
• The company reported after-hours earnings in March 2026 alongside other companies [N4].

Fortress Biotech’s recent FDA approval of ZYCUBO, the first treatment for Menkes disease in the U.S., represents a significant regulatory milestone. The successful sale of a $205 million PRV by Cyprium Therapeutics demonstrates the company’s ability to monetize valuable regulatory assets. The company’s strong liquidity position, with nearly $197 million in cash and equivalents and a current ratio near 4, supports ongoing operations and development activities. The diversified portfolio of subsidiaries and access to capital markets through equity offerings and credit facilities provide multiple avenues for growth and value creation.

Fortress Biotech faces risks related to its reliance on regulatory approvals and asset monetization, which can be uncertain and timing-dependent. The company’s net loss and negative earnings per share reported in Q2 2026 reflect ongoing operational challenges. Restrictions on the use of its shelf registration due to paused dividends on preferred stock may limit financing flexibility. The company’s credit agreements include financial covenants that, if breached, could lead to default. Additionally, the biopharmaceutical industry’s competitive and regulatory environment presents execution risks for clinical development and commercialization efforts.

Fortress Biotech’s moat is derived from its diversified portfolio of biopharmaceutical subsidiaries, each focused on niche or rare disease treatments with regulatory approvals such as ZYCUBO for Menkes disease. The company’s ability to generate value through asset monetization, including Priority Review Voucher sales, and its access to capital markets and credit facilities provide financial flexibility. However, the biopharmaceutical sector’s inherent risks, including regulatory, clinical, and financing challenges, limit the durability of competitive advantages.

• Financing and Liquidity Risks: The company’s inability to currently use its shelf registration due to paused dividends on preferred stock limits its ability to raise capital through equity offerings. Financial covenants in credit agreements require maintaining minimum liquidity and net sales thresholds, with potential default consequences.
• Regulatory and Clinical Risks: Fortress Biotech’s business depends on successful regulatory approvals and clinical development of its subsidiaries’ drug candidates. Delays or failures in these areas could adversely affect operations and asset values.
• Operational and Market Risks: The company’s net losses and negative earnings per share indicate ongoing operational challenges. Market conditions and competition in the biopharmaceutical sector may impact the company’s ability to commercialize products and generate revenue.

• Fortress Biotech, Inc. is a biopharmaceutical company with multiple subsidiaries including Journey, Mustang, Cyprium, and Avenue.
• The company filed a shelf registration statement on Form S-3 effective May 30, 2024, but lost eligibility to use it due to paused dividends on Series A Preferred Stock; eligibility is regained upon filing the next Form 10-K with all dividends paid.
• Fortress Biotech has an at-the-market offering program and has issued shares under it.
• The company has a $50 million senior secured credit agreement with Oaktree, amended to extend maturity to June 30, 2028, with interest-only payments and financial covenants including minimum liquidity and net sales tests.
• Cyprium Therapeutics, a subsidiary, sold a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million in March 2026, with proceeds partially payable to a U.S. government institute.
• Fortress Biotech reported cash and equivalents of $196.6 million and current assets of $245.5 million as of June 30, 2026, with current liabilities of $62.0 million, resulting in a current ratio of 3.96 and cash ratio of 3.17.
• For the quarter ended June 30, 2026, Fortress Biotech reported revenue of $18.7 million and a net loss of $0.468 million, with basic and diluted EPS of -$0.08 per share.
• The company’s operating cash flow improved significantly in the six months ended June 30, 2026, with net cash provided by operating activities of $144.6 million compared to net cash used in operating activities of $47.1 million in the prior year period.
• Fortress Biotech’s subsidiary Journey filed a shelf registration statement effective January 21, 2026, covering up to $150 million of securities.
• Cyprium declared a cash dividend of approximately $118.6 million in July 2026, with about $95.4 million payable to Fortress Biotech.
• Fortress Biotech announced FDA approval of ZYCUBO, the first and only approved treatment for Menkes disease in the U.S., in January 2026.
• The company has contractual obligations including leases, with a sublease agreement commenced in March 2026 for office space in New York, expected to generate $11.9 million in base rent through August 2031.
• Fortress Biotech’s subsidiaries have engaged in equity offerings, warrant exercises, and asset sales contributing to cash flows.
• The company’s financial figures and liquidity ratios are summarized from the latest SEC filings and provided for informational purposes only.